

HEART FAILURE GUIDELINES FOR U M



PROGRAM

9th edition

Live and online Forum

Hybrid from Nice, France

12th & 13th Oct.

19th Nov. 2021

3 days of interactive discussions

Understanding the heart failure guidelines development process and its implications

Live location: Nice, France

Why a Guidelines Forum on heart failure?

The quality of research and development efforts made by manufacturers of pharmacological agents, biomarkers, and medical devices has obviously had a major impact on the position of these products in clinical guidelines on the management of heart failure. Conversely, the success and failure stories that inevitably accompany the release of new guidelines may be a source of inspiration for further research and development. And, ultimately, guidelines really shape clinical practice if doctors and their patients adopt them.

A better understanding of the processes involved in guidelines development will help companies that develop drugs, biomarkers, and devices to adapt and improve their research and development programmes for the future.

This could also translate into earlier and more efficient development of diagnostic and therapeutic tools for patients.

How do guidelineers deal with the available evidence and what are their expectations in this respect? What criteria must a product or an intervention meet to be recommended by heart failure guidelines? What are the most frequent reasons for failure? Why may guidelines of geographically distinct origins but dealing with the same evidence occasionally reach different

Format

A series of short presentations and discussions with a focus on practical examples, case studies and interactivity between Faculty members.

Who should attend?


Attendees include industry representatives with interest in clinical trials, product development, market access, guidelines development and implementation, patients' advocacy specialists, clinical research organizations and payers.

About TMA

The Translational Medicine Academy (TMA) is an international academic Foundation with focused activities in Mission Critical Areas of high public health importance having significant professional and patient therapeutic and educational gaps.

9th edition

Live & online Forum



Why a Heart Failure Guidelines Forum?

The objective is to better understand the existing Heart Failure guidelines development process and its implications in clinical practice. It is not to develop new guidelines, but to gather a multidisciplinary panel of leading international experts to discuss the latest evidence, ongoing research and controversial issues that have implications for the development of clinical practice guidelines.

Educational objectives

At the end of the meeting, all participants will have a better understanding of the unmet needs and knowledge gaps that need to be addressed by future research and development efforts, and of the most appropriate ways of progressing to conciliate and take advantage of clinical, societal, evidence-based medicine and regulatory requirements.

conclusions? What should be done to avoid that guidelines being lost in translation? How can we adapt the guidelines for low and middle income countries?

Speakers and discussants who will address these topics have been selected from among the top-level North American and international experts in cardiology who participate in the regular update of guidelines. The faculty also comprises clinicians with a strong interest in translational and patient-centered medicine.

The Heart Failure Guidelines Close Forum will be strictly academic – meaning that attendees will not participate during the main sessions and discussions. However, they will be able to transmit written questions to the faculty.

Hybrid forum


A live meeting is scheduled to be held in Nice, France according to regulations.

Remote access will be possible via a secure digital and interactive platform.

This event is registered with MedTech Europe and declared (provisionally) compliant: <https://www.ethicalmedtech.eu/>

Program

9th edition
Live & online Forum

HEART FAILURE
GUIDELINES
FOR U M 

OCTOBER 12th, 2021 – 14:30-19:30 CEST

14:30–14:35: Welcome / Introductions **S. Anker**

14:35–15:10: Session 1 – Heart failure guideline process – Rules of engagement

Chairs: S Anker / G Rosano / P Seferovic

- How are the Europe guidelines developed? – M Metra
- How are the US guidelines developed? – P Heidenreich
- How are the Canadian guidelines developed? – J Ezekowitz
- How to reconcile new FDA and CMS pathways with guideline writing – B Abraham
- Discussants: G Filippatos, N Stockbridge, B Zuckerman, M Fiuza

15:10–15:55: Session 2 – Issues of Diagnosis

Chairs: S Anker / W Abraham / B Bozkurt

- The 3 “classes” of HF: HFrEF, HFmrEF & HFpEF – all good? – M Metra
- LVEF, does it still matter to differentiate groups of HFrEF patients? – J Teerlink
- General Discussion
- Pro-Hormone biomarkers for prognosis & diagnosis of HF – E Giannitsis
- What about ID assessment, now for all? – E Jankowska
- General Discussion

15:55–16:35 Session 3 – AF issues

Chairs: J Butler / A. Coats

- The evidence for anti-coagulation – J Cleland
- AF treatment in patients in HF – What do different GLs say? – P Kirchhof
- AF treatment in patients in HF – The US perspective — J Piccini
- CRT for patients with AF and HF – G Hindricks
- General Discussion

----- **16:35–16:45: BREAK** -----

16:45–18:00: Session 4 – SGLT2 inhibitors

Chairs: S Anker / J Butler

- For prevention: 5 drugs at 1A – L Lund
- In diabetic HF patients 3 drugs at 1A – G Filippatos
- In HFrEF regardless of diabetes 2 drugs at 1A – R de Boer
- What can HF guidelines learn from CKD studies with SGLT2 inhibitors – M Petrie
- General Discussion
- What about HFpEF: Is a GL-update already needed? – A Coats
- What does HFA plan for this – G Rosano
- What about SGLT2 inhibitors and changes in quality of life? Are separate recommendations needed? – J Butler
- General Discussion

18:00–19:00: Session 5 - Device for HF therapy

Chairs: W Abraham / J Butler


- Neuromodulation – F Zannad
- CCM: New Developments – J Butler
- Intra-atrial shunt devices (covering all three approaches) – W Abraham
- General Discussion
- Telemedical approaches – CardioMems & GUIDE-HF & All about Covid – M Zile
- General Discussion

19:00–19:30: Ad hoc Q & A session (part 1)

----- **In-person & Remote** -----

Program

9th edition
Live & online Forum

HEART FAILURE
GUIDELINES
FOR URM 

OCTOBER 13th, 2021 – 13:30-18:00 CEST

13:30: Welcome A. Coats

13:35–14:20: Session 6 – Acute and severe HF related issues

Chairs: PC Schulze / O Chioncel

- Can (or should) GLs recommend drugs before regulatory approval, and if so, how?
The vericiguat case – B. Pieske
- Starting all HFrEF drugs in hospital? – P Ponikowski
- Do Guidelines need to define up-titration steps and speed? – I Piña
- What about Omecamtiv Mecarbil? – J Teerlink
- General Discussion

14:20–14:40: Session 7 – Co-morbidities and enablement strategies part 1 (obesity)

Chairs: J Butler / B Pieske

- Weight management in HF to improve exercise capacity with GLP1 agonists? – M Packer
 - Weight management in HFpEF to prevent hard outcomes – J Butler
- General Discussion

14:40–15:15: Session 8 – Co-morbidities and enablement strategies part 2 (HK & ID)

Chairs: J Butler / S Zieroth

- Treatment of hyperkalemia – M Kosiborod
- ID: The European Perspective – P Ponikowski
- ID / Anemia: The US Perspective – A Hernandez
- General Discussion

15:15–15:50: Session 9 – Device for HF therapy part 1: focus on valvular heart disease

Chairs: W Abraham / S Anker

- Targeting FMR: MitraClip – W Abraham

- Targeting FMR: Carillon – St von Bardeleben
- Targeting TR: (Edwards / Pascal system) – J Hausleiter
- General Discussion

----- **15:50–16:00: BREAK** -----

16:00–16:50: Session 10 – Controversial issues about ESC guidelines

Chairs: S Anker / PC Schulze / A Coats

GUIDED GROUP DISCUSSION

- Why 1B for entresto?
- Entresto after ACE inhibitors or straight away?
- 2B for Vericiguat, really?
- Why not class 1 for drugs that improve QoL & functional status more reliable than exercise?
- Is 1A for sotaglifozin in diabetic heart failure patients a surprise?
- Dual SGLT1 and SGLT2 inhibition: does it matter?
- The original "CardioMems restricted to LVEF $\leq 35\%$ " statement and how it got correct in the printed version.

16:50–17:30: Session 11 – Open issues

Chairs: S Anker / P Ponikowski

GUIDED GROUP DISCUSSION

- Dual SGLT1 and SGLT2 inhibition: does it matter? – D Bhatt
- Personalised approach and patients profiles – when do you give ivabradine?
- HFmEF: now 2B for subgroups?!
- Finerenone and its success in DKD \rightarrow something for HF already?
- Separate QoL recommendations for SGLT2 inhibitors? (the Preserved-HF case)
- Do we need a phenotyping approach for HFpEF as well?

17:30–18:00: Ad hoc Q & A session (part 2)

Conclusion: S Anker

----- **In-person & Remote** -----

Program

9th edition
Live & online Forum

HEART FAILURE
GUIDELINES
FORUM 

NOVEMBER 19th, 2021 – 15:30-19:00 CET

15:30–15:35: Welcome and summary of past discussions

15:35 -16:40: Session 12 – New HF trial results

Chairs: S Anker / J Butler

- GALACTIC-HF – J Teerlink
- AFFIRM-HF and more on Iron – P Ponikowski
- EMPEROR-Preserved – J Butler
- News on AF in HF – M Vaduganathan
- News on PRESERVED-HF – M Kosiborod
- News on EMPULSE – A Voors
- News on CHIEF-HF - J Spertus
- General Discussion

16:40 –16:55: Ad hoc Q & A session (part 3)

16:55–17:10: Session 13 – Revisiting possible treatment algorithms after the AHA (part 1)

GUIDED GROUP DISCUSSION

- Acute HF – all faculty
- General Discussion

17:10–17:30: Session 14 – Revisiting possible treatment algorithms after the AHA (part 2)

Chairs: J Butler / A Coats

GUIDED GROUP DISCUSSION

- HF_rEF – M&M oriented – all faculty
- HF_rEF – symptoms – all faculty
- General Discussion

----- **17:30–17:40:** BREAK -----

17.40 -18.00: Session 15 - Revisiting AFib in different guidelines

Chairs: S Anker / J Butler

- Why Dronedaron was included in the E.U. Guidelines for HFpEF - J Camm
- General Discussion

18:00–18:20: Session 16 – Revisiting possible treatment algorithms after the AHA (part 3)

Chairs: S Anker / J Butler

- HFpEF & HFmrEF – all faculty
- General Discussion

18:20–18:45: Session 17 – Guidelines implementation and International cascade guidelines

Chairs: S Anker / A Coats

18:45–18:55: Ad hoc Q & A session (part 3)

18:55–19:00: Conclusions & End of Meeting

----- Remote -----

Information

9th edition
Live & online Forum

HEART FAILURE
GUIDELINES
FORUM 

Chairs



Prof. Javed Butler

MD, MPH, MBA
Professor and Chairman of the
Department of Medicine at
the University of Mississippi in
Jackson, Mississippi, USA, Patrick
H. Lehan Chair in cardiovascular
Research, Professor of physiology



Prof. William Abraham

MD, FACP, FACC, FAHA, FESC,
FRCPE
Professor of Medicine,
Physiology, and Cell Biology
College of Medicine,
Distinguished Professor, Division
of Cardiovascular Medicine, the
Ohio State University, USA



Prof. Stefan Anker

MD, PhD, FESC
Professor of cardiology and
Cachexia Research, Department
of Cardiology Charité Campus
Virchow-Klinikum Berlin,
Germany



Prof. Andrew Coats

DM, DSc, MBA, AO
President-elect, Heart Failure
Association of the ESC, Academic
Vice-President Monash-Warwick
Alliance, Monash University,
Melbourne, Australia, University
of Warwick, Coventry, UK

Faculty

EUROPE

S Anker
J Camm
O Chioncel
J Cleland
R de Boer
G Filippatos
E Giannitsis
G Hindricks

J Hausleiter
E Jankowska
P Kirchhoff
L Lund
M Metra
M Petrie
B. Pieske
P Ponikowski

G Rosano
G. Savarese
PC Schulze
P Seferovic
C. Tschöpe
S von Bardeleben
A Voors
F Zannad

USA/
CANADA

W Abraham
D Bhatt
B Bozkurt
J Butler
J Ezekowitz
M Fiuzat
P Heidenreich
A Hernandez

M Kosiborod
J Lindenfeld
W McMurray
M Packer
J Piccini
I Piña
J.S. Spertus
S Solomon

N Stockbridge
J Teerlink
M Vaduganathan
S Zieroth
B Zuckerman
M Zile

ASIA

V Chopra
AJS Coats
J Zhang
Y Zhang

Location

AC by Marriott Nice
Forum C
59 Promenade des Anglais
06000 Nice – France
www.achotelnice.com

Contact us

Organization
Charles Schoen - Operations Director
Tel.: +33 (0) 6 08 18 77 08
Email: charles.schoen@tmacademy.org

Registration & Sponsorship
Fabrice Poller
Tel: +33 (0) 6 99 66 19 73
Email: fpoller@tmacademy.org

www.tmacademy.org